IL-5-induced migration via ERK1/2-mediated MMP-9 expression by inducing activation of NF-κB in HT1376 cells

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 1084-1090

  Lee, Eo Jin ^a,c   Park, Sung Soo ^b   Kim, Wun Jae ^c   Moon, Sung Kwon ^a,c  

^a Chungju National University   (South Korea)

^b Cheju Halla University   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

Bladder cancer cells; IL 5R ; Interleukin 5; Migration; MMP 9

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR ALPHA; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BINDING AFFINITY; BINDING SITE; BLADDER CANCER; CANCER CELL; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; TRANSCRIPTION INITIATION; WOUND HEALING;

5' FLANKING REGION; BUTADIENES; CELL LINE, TUMOR; CELL MOVEMENT; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-5; INTERLEUKIN-5 RECEPTOR ALPHA SUBUNIT; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; NITRILES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA INTERFERENCE; TRANSCRIPTION FACTOR AP-1;

EID: 84865318564     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1857     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Black PC and Dinney CP: Bladder cancer angiogenesis and metastasis - translation from murine model to clinical trial. Cancer Metastasis Rev 26: 623-634, 2007.
3. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121-125, 1990.
4. Liotta LA: Tumor invasion and metastasis-role of extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 46: 1-7, 1986.
5. Sier CF, Casetta G, Verheijen JH, et al: Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res 6: 2333-2340, 2000.
6. Davies B, Waxman J, Wasan H, et al: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53: 5365-5369, 1993.
7. Nutt JE, Durkan GC, Mellon JK and Lunec J: Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine. BJU Int 91: 99-104, 2003.
8. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC and Freeman MR: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58: 1395-1399, 1998.
9. Di Carlo A, Terracciano D, Mariano A and Macchia V: Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Oncol Rep 15: 1321-1326, 2006.
10. Kumar B, Koul S, Petersen J, et al: p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 70: 832-841, 2010.
11. Mook OR, Frederiks WM and Van Noorden CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705: 69-89, 2004.
12. Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
13. Busti C, Falcinelli E, Momi S and Gresele P: Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med 5: 13-25, 2010.
14. Takatsu K and Nakajima H: IL-5 and eosinophilia. Curr Opin Immunol 20: 288-294, 2008.
15. Adachi T and Alam R: The mechanism of IL-5 signal transduction. Am J Physiol 275: C623-C633, 1998.
16. Moon SK, Cha BY and Kim CH: ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: involvement of the ras dependent pathway. J Cell Physiol 198: 417-427, 2004.
17. Wu HK, Hirai H, Inamori K, Kitamura K and Takaku F: Antitumor effects of interleukin-4 and interleukin-5 against mouse B cell lymphoma and possible mechanisms of their action. Jpn J Cancer Res 83: 200-210, 1992.
18. Masuda Y, Mita S, Sakamoto K, Ishiko T and Ogawa M: Suppression of in vivo tumor growth by the transfection of the interleukin-5 gene into colon tumor cells. Cancer Immunol Immunother 41: 325-330, 1995.
19. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
20. Tyagi P, Barclay D, Zamora R, et al: Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 42: 629-635, 2010.
21. Michaud DS: Chronic inflammation and bladder cancer. Urol Oncol 25: 260-268, 2007.
22. Dinney CP, Fishbeck R, Singh RK, et al: Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 154: 1532-1538, 1995.
23. Mian BM, Dinney CP, Bermejo CE, et al: Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res 9: 3167-3175, 2003.
24. Kader AK, Liu J, Shao L, et al: Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 13: 2614-2620, 2007.
25. Lee SJ, Park SS, Lee US, Kim WJ and Moon SK: Signaling pathway for TNF-alpha-induced MMP-9 expression: mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells. Int Immunopharmacol 8: 1821-1826, 2008.
26. Cho A, Graves J and Reidy MA: Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20: 2527-2532, 2000.
27. Wiehler S, Cuvelier SL, Chakrabarti S and Patel KD: p38 MAP kinase regulates rapid matrix metalloproteinase-9 release from eosinophils. Biochem Biophys Res Commun 315: 463-470, 2004.
28. Yao J, Xiong S, Klos K, et al: Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20: 8066-8074, 2001.
29. Genersch E, Hayess K, Neuenfeld Y and Haller H: Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. J Cell Sci 113: 4319-4330, 2003.
30. Lee SJ, Park SS, Cho YH, et al: Activation of matrix metalloproteinase- 9 by TNF-alpha in human urinary bladder cancer HT1376 cells: the role of MAP kinase signaling pathways. Oncol Rep 19: 1007-1013, 2008.
31. Chang HR, Huang HP, Kao YL, et al: The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells. Chem Biol Interact 183: 172-180, 2010.
32. Takaki S, Murata Y, Kitamura T, Miyajima A, Tominaga A and Takatsu K: Reconstitution of the functional receptors for murine and human interleukin 5. J Exp Med 177: 1523-1529, 1993.
33. Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 12-22, 2004.